MedPath

Clinical Evaluation of Using Intense Pulsed Light for Improving the Appearance of Striae Distensae

Not Applicable
Terminated
Conditions
Striae Distensae
Interventions
Device: Venus Versa
Registration Number
NCT02452359
Lead Sponsor
Venus Concept
Brief Summary

This trial is intended to evaluate the effect of IPL treatment on the Striae Distensae. The study hypothesis is that the SR580 applicator will improve the appearance of Striae Distensae by at least 1 point on the Global Aesthetic Improvement ScaleI (GAIS) at 3 months follow-up compared to baseline in at least 50% of the study population.

Detailed Description

Study Design This is a multi-site, prospective, open labeled clinical trial with before-after study design. This study will include up to 8 visits at the clinic: initial screening/consultation, 5 treatments, visits in 2 week intervals, and 2 follow-up visits at 1 and 3 months after the last treatment visit.

Up to 60 healthy subjects age 24-65 with Striae Distensae will be enrolled.

Study duration:

Duration of subject's participation: Up to 5.5 months from enrollment to termination

Blinding Objective assessment of clinical improvement by global assessment scale will be achieved by sending before/after pictures (baseline/3months after last treatment) to 3 blinded reviewers at the end of the study.

Study Procedures Test Spots Up to 3 test spots will be performed in the selected treatment area to determine the optimal parameters / settings

Treatment visits Each subject will be enrolled and scheduled for 5 treatments at 2 week intervals and return for follow-up visits at one month and 3 months after the last treatment for evaluation of the treated areas. The duration of the entire treatment visit is approximately 60 minutes.

Treatment The treatment areas are divided into 2 treatment areas: abdomen or thighs. Apply a thin layer of IPL gel. Place the applicator in close contact, perpendicular to the skin with no pressure applied. Pressing the applicator will fire the IPL pulse.

Administer pulses throughout the treated area to ensure full coverage of the treated area with applicator overlap approximately 1/3 of the previously treated skin.

A single pass over the area is completed Remove the remnants of the IPL gel and dry thoroughly. Cold air or cold, wet but not frozen gauze pads may be placed on the treated area for post treatment cooling.

Typical responses to the treatment are mild erythema and edema.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
54
Inclusion Criteria
  1. Able to provide written Informed Consent;
  2. Healthy male or female, 24-65 years Fitzpatrick-Goldman skin type I-V;
  3. Having visible Striae Distensae to be treated (abdomen/thighs);
  4. Comply with the treatment/follow-up schedule and requirements;
  5. Women of child-bearing age are required to be using a reliable method of birth control
Exclusion Criteria
  1. Fitzpatrick-Goldman skin type VI;
  2. Pregnant, intending to become pregnant during the course of study, less than 3 months postpartum or less than 6 weeks after breastfeeding;
  3. Heavy smoker
  4. Unable or unlikely to refrain from tanning
  5. Use of photosensitive medication
  6. Use of oral isotretinoin within 3 months
  7. Any dermal/epidermal damage or disorder in treated area
  8. Prior treatment in treated area within 3 months
  9. Prior skin laser/light or another device treatment in treated area within 6 months
  10. Prior use of collagen, fat injections or other methods of skin augmentation in treated area within 12 months
  11. Prior use of Botox in treatment area within 6 months
  12. Prior ablative resurfacing procedure with laser in treatment area within 12 months
  13. Any other surgery in treated area within 9 months
  14. Participation in a study of another investigational device or drug as per the Investigator's discretion
  15. History of keloid or any other type of hypertrophic scar formation or poor wound healing in a previously injured skin area
  16. Showing symptoms of hormonal disorders (such as Melasma, Chloasma);
  17. Concurrent inflammatory skin conditions, open laceration or abrasion of any sort on area to be treated during the course of treatment
  18. Active Herpes Simplex at the time of treatment or having experienced more than three episodes of Herpes Simplex eruption within a year of study
  19. Multiple dysplastic nevi in area to be treated
  20. Having a bleeding disorder or taking anticoagulation medications
  21. History of immunosuppression/immune deficiency disorders
  22. Having any form of active cancer at the time of enrollment and during the course of the study or history of skin cancer
  23. Pigmented lesion in the treated area that appears cancerous
  24. Significant concurrent illness, such as uncontrolled diabetes
  25. Active infections in the treated area

28.Tattoo or permanent makeup at the treatment area. 29.Mentally incompetent, prisoner or evidence of active substance or alcohol abuse 30.Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or for the study personnel) to treat the subject as part of this research study

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Treatment GroupVenus VersaGroup receiving treatment with Venus Versa IPL energy
Primary Outcome Measures
NameTimeMethod
Improvement in Striae Distensae Appearance90 days following last IPL treatment

Striae distensae appearance improvement by at least 1 point on the Global Aesthetic Improvement scale (GAIS) from photographs 3 months following the last treatment as determined by 3 blinded reviewers where 3 = Very Much Improved, 2 = Much Improved, 1 = Improved, 0 = No Change, -1 = Worse, -2 = Much Worse and -3 = Very Much Worse.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Rosenberg Plastic Surgery

🇺🇸

Beverly Hills, California, United States

© Copyright 2025. All Rights Reserved by MedPath